<DOC>
	<DOCNO>NCT00487747</DOCNO>
	<brief_summary>This single arm study ass efficacy safety PEGASYS patient chronic hepatitis B either treatment-naive , fail lamivudine- interferon-treatment past . All patient receive PEGASYS , 180 microgram s.c. weekly 48 week , follow 48 week treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With Chronic Hepatitis B .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , 1870 year age ; chronic hepatitis B ; Hepatitis B Virus ( HBV ) DNA &gt; 100,000 copies/mL . previous antiviral interferonbased therapy chronic hepatitis B past 6 month ; evidence decompensated liver disease ; history evidence medical condition associate chronic liver disease viral hepatitis ; coinfection hepatitis A , C D , HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>